Tinengotinib

Small molecule

Also known as TT-00420

Phase 3underway

Evidence outlook · registrational

Cholangiocarcinoma: registrational readout pending

Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2026-12.

NCT05253053: This was a nonrandomized, open-label study with three treatment arms and no placebo or active comparator; 84 participants were enrolled. Its primary outcomes concerned treatment-related adverse events, laboratory abnormalities, and dose-limiting toxicity, and no primary endpoint results have been posted.

Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Cholangiocarcinoma
Phase 2 (5)
Cholangiocarcinoma
NCT06057571 · TransThera Sciences (Nanjing), Inc.
2023-11-17 – 2025-12-31 · Cholangiocarcinoma Metastatic
What this study did
NCT04919642 · TransThera Sciences (Nanjing), Inc.
2021-12-07 – 2024-02-28 · Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
What this study did
HR+/HER2- Metastatic Breast Cancer
Other / comorbidity
NCT07871110 · TransThera Sciences (Nanjing), Inc.
2026-09-18 – 2029-06-30 · Prostate Cancer (CRPC)
What this study did
NCT07052253 · Akeso
2025-07-18 – 2027-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
Phase 1/2 (4)
Cholangiocarcinoma
Other / comorbidity
NCT06457919 · Memorial Sloan Kettering Cancer Center
2024-06-04 – 2027-06 · Prostate Cancer
What this study did
NCT06221774 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2024-02-01 – 2025-11-30 · Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer
What this study did
Phase 1 (2)
Other / comorbidity
NCT03654547 · TransThera Sciences (Nanjing), Inc.
2019-01-08 – 2024-02-28 · Advanced Solid Tumors, Triple Negative Breast Cancer
What this study did
NCT04705922 · TransThera Sciences (Nanjing), Inc.
2020-12-29 – 2021-07-23 · Healthy
What this study did

Competitive landscape

This drug's own stage for Cholangiocarcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tinengotinib: this drugPhase 3Small moleculeAurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)Weak signalFeatured results are safety only in this race
Futibatinib (Lytgobi)ApprovedSmall moleculeFGFR (FGFR1/2/3/4)Weak signalNo reviewed efficacy summary in this indication
Lirafugratinib (Lyrfigtu)ApprovedSmall moleculeFGFR2not yet gradedNo reviewed efficacy summary in this indication
Pemigatinib (Pemazyre)ApprovedSmall moleculeFGFR1/2/3Weak signalNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tinengotinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3CholangiocarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT05948475 · CT.gov ↗
What to watch
2027 (3)
May 2027 (1)
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-05-10 · NCT07052253 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1/2Prostate CancerRecruiting
Est. primary completion 2027-06 · NCT06457919 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT07498478 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 2Prostate Cancer (CRPC)Recruiting
Est. primary completion 2028-12-31 · NCT07871110 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 3CholangiocarcinomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07328919 · CT.gov ↗
What to watch

See the full readout calendar ↗